Skye Bioscience, Inc.
SKYE · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | -0.09 | -0.02 | 0.19 |
| FCF Yield | 5,532.69% | -14,579.34% | -7.27% | -4.47% |
| EV / EBITDA | -8.16 | -1.56 | -4.69 | -23.88 |
| Quality | ||||
| ROIC | -41.43% | -19.71% | -15.55% | -12.52% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.05 | 0.61 | 827.27 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 199.78% | -111,679.76% | -21.27% | 4.84% |
| Safety | ||||
| Net Debt / EBITDA | 1.35 | 4.21 | 7.07 | 18.98 |
| Interest Coverage | 0.00 | -8,099.17 | 24.88 | -32.71 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,550.39 | -869.58 | -292.27 | -1,063.72 |